Pds biotechnology announces feature in “grand rounds” webinar hosted by alliance global partners and conference call and webcast for third quarter 2020 financial results

Florham park, n.j., oct. 29, 2020 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the company's proprietary versamune® t-cell activating technology, today announced that the company will be featured in a live webinar, “grand rounds: a webinar in biotech and specialty pharma,” hosted by james molloy, managing director of equity research, biotechnology and specialty pharmaceuticals at alliance global partners, on monday, november 2nd at 10:30 am eastern time.
PDSB Ratings Summary
PDSB Quant Ranking